Pharmaceuticals & Therapeutics

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

Armed with $320M in new capital, Anteris will showcase its revolutionary biomimetic heart valve to top investors. Can it disrupt a market of giants?

A new EU directive to clean wastewater could make essential generic medicines unprofitable, sparking fears of widespread shortages across the continent.

A Swiss firm begins human trials for a non-glucose dialysis solution, aiming to end a 30-year reliance on problematic treatments for kidney patients.

With stockholder approval, Abbott's acquisition of Exact Sciences is set to reshape the cancer diagnostics landscape and accelerate early detection.

The FDA is reviewing a new, more affordable alternative to the costly arthritis drug Orencia, potentially saving patients and the healthcare system billions.

Guerbet's Elucirem™ gains FDA approval for patients aged 0-2, halving gadolinium exposure in the most vulnerable without sacrificing diagnostic quality.

Dr. Joss Reimer, a veteran of Manitoba's COVID-19 response, takes the helm at PHAC, facing a slate of crises from measles to misinformation.

New data on leronlimab reveals striking long-term survival signals in heavily pretreated mTNBC patients, hinting at a new way to fight the disease.

ABLi Therapeutics reports its drug risvodetinib is the first to lower toxic alpha-synuclein levels in a Phase 2 trial, heralding a new era for patients.

enGene hits the road for key investor conferences, showcasing a promising non-viral gene therapy for a tough-to-treat bladder cancer. Will it succeed?

The biotech firm landed $1M at a premium, a sign of investor faith. But with past regulatory hurdles, can this cash pave a new path for its NurOwn® therapy?

Travere Therapeutics reports a profitable Q4 driven by its kidney drug FILSPARI, but a revenue miss and a critical FDA decision create a complex outlook.

A landmark bill to shield living organ donors from job and insurance discrimination is advancing in the Senate, offering new hope for 90,000+ on the waiting list.

INmune Bio will present key Phase III results for CORDStrom, a systemic cell therapy for the devastating rare skin disease RDEB. Will it be a breakthrough?

A renewed deal between Inmar Intelligence and Premier, Inc. highlights the vital, unseen role of reverse logistics in pharmacy finance, compliance, and safety.

A new study reveals a breakthrough hair loss system offers clinically meaningful regrowth for menopausal women in just four months, challenging existing treatments.

In memory of Brynne Coletti, a family's transformational $10M gift will create a new women's cancer program, bringing world-class care to Southwest Florida.

Clene Inc. faces investors with promising data for ALS and MS, but a looming cash crunch makes its upcoming conference a critical test of survival.

New five-year data for SYFOVRE shows a significant delay in geographic atrophy progression, offering long-term hope but also sparking clinical debate.